Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis

Autor: Heather Jones, Annette Szumski, Robert Landewé, Maxime Dougados, Anna Molto, Bonnie Vlahos, Walter P. Maksymowych, Pascal Claudepierre, Ron Pedersen, Désirée van der Heijde, Robert G. W. Lambert, Jack F. Bukowski, Manouk de Hooge
Přispěvatelé: Clinical Immunology and Rheumatology, AII - Inflammatory diseases, VO, alexandra, University of Alberta, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Universiteit Gent = Ghent University (UGENT), Leiden University Medical Center (LUMC), Amsterdam UMC - Amsterdam University Medical Center, Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Pfizer, Syneos Health [Wilmington], Hôpital Cochin [AP-HP], Universiteit Gent = Ghent University [Belgium] (UGENT)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Canada
lcsh:Diseases of the musculoskeletal system
Sacroiliac joint
Severity of Illness Index
Etanercept
Lesion
Cohort Studies
Anti-TNF
Internal medicine
Spondylarthritis
medicine
Medicine and Health Sciences
Humans
Spondylitis
Ankylosing
Axial spondyloarthritis
Ankylosing spondylitis
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
medicine.diagnostic_test
business.industry
Biology and Life Sciences
Magnetic resonance imaging
medicine.disease
Magnetic Resonance Imaging
Rheumatology
medicine.anatomical_structure
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
ASDAS
Cohort
medicine.symptom
lcsh:RC925-935
business
medicine.drug
Cohort study
Research Article
MRI
Zdroj: Arthritis research & therapy, 23(1):43. BioMed Central
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-14 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy, 2021, 23 (1), pp.43. ⟨10.1186/s13075-021-02428-8⟩
ARTHRITIS RESEARCH & THERAPY
Arthritis Research & Therapy, BMC, 2021, 23 (1), pp.43. ⟨10.1186/s13075-021-02428-8⟩
Arthritis Research and Therapy, 23(1). BMC
ISSN: 1478-6354
1478-6362
Popis: Background Limited information is available on the impact of treatment with a tumor necrosis factor inhibitor (TNFi) on structural lesions in patients with recent-onset axial spondyloarthritis (axSpA). We compared 2-year structural lesion changes on magnetic resonance imaging (MRI) in the sacroiliac joints (SIJ) of patients with recent-onset axSpA receiving etanercept in a clinical trial (EMBARK) to similar patients not receiving biologics in a cohort study (DESIR). We also evaluated the relationship between the Ankylosing Spondylitis Disease Activity Score (ASDAS) and change in MRI structural parameters. Methods The difference between etanercept (EMBARK) and control (DESIR) in the net percentage of patients with structural lesion change was determined using the SpondyloArthritis Research Consortium of Canada SIJ Structural Score, with and without adjustment for baseline covariates. The relationship between sustained ASDAS inactive disease, defined as the presence of ASDAS Results This study included 163 patients from the EMBARK trial and 76 from DESIR. The net percentage of patients with erosion decrease was significantly greater for etanercept vs control: unadjusted: 23.9% vs 5.3%; P = 0.01, adjusted: 23.1% vs 2.9%; P = 0.01. For the patients attaining sustained ASDAS inactive disease on etanercept, erosion decrease was evident in significantly more than erosion increase: 34/104 (32.7%) vs 5/104 (4.8%); P Conclusions These data show that a greater proportion of patients achieved regression of erosion with versus without etanercept. However, the link between achieving sustained ASDAS inactive disease and structural lesion change on MRI could not be clearly established. Trial registration EMBARK: ClinicalTrials.gov identifier: NCT01258738, Registered 13 December 2010; DESIR: ClinicalTrials.gov identifier: NCT01648907, Registered 24 July 2012.
Databáze: OpenAIRE
Externí odkaz: